Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
2 hedge funds and large institutions have $100K invested in Sonnet BioTherapeutics in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
15% less capital invested
Capital invested by funds: $118K → $100K (-$18K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
+$45.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$11K |
| 2 |
QCIG
Quad-Cities Investment Group
Davenport,
Iowa
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Renaissance Technologies
New York
| $34K | – | – | – |
|
|
2
Truist Financial
Charlotte,
North Carolina
| $22K | +$45.3K | +1 | New |
|
3
Citadel Advisors
Miami,
Florida
| $14K | – | – | – |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $12K | – | – | – |
|
5
BlackRock
New York
| $7K | – | – | – |
|
|
SI
6
Stephens Inc
Little Rock,
Arkansas
| $6K | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $3K | – | – | – |
|
8
UBS Group
Zurich,
Switzerland
| $2K | – | – | – |
|
|
9
Jane Street
New York
| – | -$11K | – | – |
|
|
QCIG
10
Quad-Cities Investment Group
Davenport,
Iowa
| – | -$4K | – | – |
|
SONN Hedge Fund Activity: Q4 2019 in Review
2 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q4 2019, worth a combined $100K — down 15% from $118K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new SONN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Truist Financial, opening a new position worth an estimated $45.3K. The largest seller was Jane Street, cutting an estimated $11K.
- 2 institutional investors held Sonnet BioTherapeutics (SONN) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $100K of Sonnet BioTherapeutics stock for Q4 2019, down 15% quarter-over-quarter.
- 1 fund opened new Sonnet BioTherapeutics positions in Q4 2019 and 0 closed out, a net change of +1 holder.
- The largest Sonnet BioTherapeutics buyer in Q4 2019 was Truist Financial, an estimated $45.3K added.
- The largest Sonnet BioTherapeutics seller in Q4 2019 was Jane Street, an estimated $11K sold.
Based on aggregated 13F filings for Q4 2019.